• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review.指甲银屑病及其治疗对生活质量的影响:一项系统评价。
Skin Appendage Disord. 2021 Feb;7(2):83-89. doi: 10.1159/000512688. Epub 2021 Jan 22.
2
Patient Satisfaction with Treatment for Onychocryptosis: A Systematic Review.患者对嵌甲治疗的满意度:一项系统评价。
Skin Appendage Disord. 2020 Sep;6(5):272-279. doi: 10.1159/000508927. Epub 2020 Jul 17.
3
Interventions for nail psoriasis.指甲银屑病的干预措施。
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD007633. doi: 10.1002/14651858.CD007633.pub2.
4
Nail Psoriasis, the unknown burden of disease.甲银屑病,未知的疾病负担。
J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1690-5. doi: 10.1111/jdv.12368. Epub 2014 Jan 15.
5
Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.阿达木单抗在常规临床实践中治疗中度至重度斑块状银屑病患者头皮和指甲病变的有效性。
Acta Dermatovenerol Alp Pannonica Adriat. 2017 Mar;26(1):11-14. doi: 10.15570/actaapa.2017.3.
6
Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome.托法替尼治疗关节炎、痤疮、脓疱病、骨质增生、骨炎综合征伴发的指甲病变和掌跖脓疱病。
JAMA Dermatol. 2021 Jan 1;157(1):74-78. doi: 10.1001/jamadermatol.2020.3095.
7
Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.阿达木单抗治疗中重度银屑病:BELIEVE研究中对头皮和指甲影响的亚组分析。
J Eur Acad Dermatol Venereol. 2015 Feb;29(2):353-360. doi: 10.1111/jdv.12553. Epub 2014 May 21.
8
Efficacy of Systemic Treatments of Nail Psoriasis: A Systemic Literature Review and Meta-Analysis.甲银屑病全身治疗的疗效:一项系统文献综述与荟萃分析。
Front Med (Lausanne). 2021 Feb 10;8:620562. doi: 10.3389/fmed.2021.620562. eCollection 2021.
9
Nail psoriasis as a severity indicator: results from the PsoReal study.指甲银屑病作为一种严重程度指标:来自PsoReal研究的结果。
Patient Relat Outcome Meas. 2011 Jul;2:1-6. doi: 10.2147/PROM.S14861. Epub 2010 Dec 22.
10
Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.患者生活质量与儿童银屑病严重程度和范围改善的相关性。
JAMA Dermatol. 2020 Jan 1;156(1):72-78. doi: 10.1001/jamadermatol.2019.3717.

引用本文的文献

1
Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.平衡疗效与肝毒性:银屑病治疗中口服药物的综合综述
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 25. doi: 10.1007/s00210-025-04334-1.
2
Clinical Trials in Nail Psoriasis: Cross-Sectional Analysis of the Current State of Research.指甲银屑病的临床试验:研究现状的横断面分析
Skin Appendage Disord. 2025 Jun;11(3):232-244. doi: 10.1159/000542568. Epub 2024 Nov 12.
3
Unveiling Psoriasis: Delving into Pathogenesis, Treatment Breakthroughs, and Patent Trends.揭开银屑病的面纱:深入探讨发病机制、治疗突破及专利趋势。
Recent Adv Inflamm Allergy Drug Discov. 2025;19(1):31-45. doi: 10.2174/0127722708307214240628042627.
4
Agreement Between Nail Psoriasis Severity Index Scores by a Convolutional Neural Network and Dermatologists: A Retrospective Study at an Academic New York City Institution.卷积神经网络与皮肤科医生对甲银屑病严重程度指数评分的一致性:纽约市一所学术机构的回顾性研究
Am J Clin Dermatol. 2025 Mar 17. doi: 10.1007/s40257-025-00934-y.
5
Inflammatory Nail Disorders in Skin of Color: A Systematic Review of Clinical and Onychoscopic Manifestations.有色人种皮肤中的炎症性甲病:临床和甲镜表现的系统评价
Int J Dermatol. 2025 Jun;64(6):1013-1020. doi: 10.1111/ijd.17680. Epub 2025 Feb 11.
6
Botulinum toxin injection shows promise in nail psoriasis: A comparative randomized controlled trial.肉毒杆菌毒素注射在甲银屑病治疗中显示出前景:一项比较随机对照试验。
JAAD Int. 2024 Apr 30;16:105-111. doi: 10.1016/j.jdin.2024.03.021. eCollection 2024 Sep.
7
Nails in older adults.老年人的指甲问题。
Ann Med. 2024 Dec;56(1):2336989. doi: 10.1080/07853890.2024.2336989. Epub 2024 May 13.
8
Development and Validation of a Patient-Reported Outcome Measure for Fingernail and Toenail Conditions: The NAIL-Q.一种用于指甲疾病的患者报告结局量表的开发与验证:NAIL-Q量表
Clin Cosmet Investig Dermatol. 2023 Oct 27;16:3091-3105. doi: 10.2147/CCID.S429120. eCollection 2023.
9
Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review.布罗达单抗治疗局限于难治部位的斑块状银屑病:一篇叙述性综述。
Dermatol Pract Concept. 2023 Jul 1;13(3):e2023245. doi: 10.5826/dpc.1303a245.
10
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review.指甲银屑病靶向治疗的疗效和安全性:系统评价。
Am J Clin Dermatol. 2023 Sep;24(5):695-720. doi: 10.1007/s40257-023-00786-4. Epub 2023 May 20.

本文引用的文献

1
Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy.阿达木单抗连续治疗24个月对甲银屑病的疗效。
Acta Derm Venereol. 2020 Jul 28;100(14):adv00214. doi: 10.2340/00015555-3545.
2
Psoriasis causes as much disability as other major medical diseases.银屑病导致的残疾程度与其他主要医学疾病相当。
J Am Acad Dermatol. 2020 Jan;82(1):256-257. doi: 10.1016/j.jaad.2018.07.059.
3
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.美国皮肤病学会-国家银屑病基金会联合指南:儿童银屑病患者的管理和治疗。
J Am Acad Dermatol. 2020 Jan;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049. Epub 2019 Nov 5.
4
Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus.成人无或轻度皮肤银屑病患者指甲银屑病的定义、评估和治疗推荐:皮肤科医生和指甲专家小组共识。
J Am Acad Dermatol. 2019 Jul;81(1):228-240. doi: 10.1016/j.jaad.2019.01.072. Epub 2019 Feb 5.
5
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.司库奇尤单抗治疗指甲银屑病的临床疗效和疾病负担的影响:随机安慰剂对照 TRANSFIGURE 试验的 32 周结果。
Br J Dermatol. 2019 Nov;181(5):954-966. doi: 10.1111/bjd.17351. Epub 2019 Jan 16.
6
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.阿达木单抗治疗甲银屑病:3 期随机安慰剂对照试验前 26 周的疗效和安全性。
J Am Acad Dermatol. 2018 Jan;78(1):90-99.e1. doi: 10.1016/j.jaad.2017.08.029. Epub 2017 Oct 6.
7
Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.阿达木单抗在常规临床实践中治疗中度至重度斑块状银屑病患者头皮和指甲病变的有效性。
Acta Dermatovenerol Alp Pannonica Adriat. 2017 Mar;26(1):11-14. doi: 10.15570/actaapa.2017.3.
8
Incidence, clinical manifestations and clipping of nail psoriasis in the dermatology center of the Hospital Universitário Evangélico de Curitiba.库里蒂巴福音大学医院皮肤科中心甲银屑病的发病率、临床表现及手术夹闭治疗
An Bras Dermatol. 2016 May-Jun;91(3):300-5. doi: 10.1590/abd1806-4841.20164296.
9
Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.在现实临床实践中,斑块型银屑病患者接受英夫利昔单抗治疗98周期间与健康相关的生活质量改善情况。
Qual Life Res. 2016 Aug;25(8):2031-40. doi: 10.1007/s11136-015-1224-z. Epub 2016 Feb 11.
10
Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data.确定皮肤病生活质量指数(DLQI)的最小临床重要差异和反应性:更多数据
Dermatology. 2015;230(1):27-33. doi: 10.1159/000365390. Epub 2015 Jan 20.

指甲银屑病及其治疗对生活质量的影响:一项系统评价。

The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review.

作者信息

Stewart Claire R, Algu Leah, Kamran Rakhshan, Leveille Cameron F, Abid Khizar, Rae Charlene, Lipner Shari R

机构信息

Weill Cornell Medical College, New York, New York, USA.

Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.

出版信息

Skin Appendage Disord. 2021 Feb;7(2):83-89. doi: 10.1159/000512688. Epub 2021 Jan 22.

DOI:10.1159/000512688
PMID:33796553
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7991285/
Abstract

At least 80% of patients with psoriasis will have nail involvement during their lifetimes. Understanding quality of life (QoL) impact of this condition and associated treatments is of utmost importance. Study objectives were to review the available literature describing patient-reported QoL outcomes in nail psoriasis and relationship with disease severity and treatment. A literature search was performed for English-language articles published prior to August 1, 2020. Articles were included in the review if primary data and validated patient-reported outcome measures assessing QoL were presented, and nail involvement was specifically examined. Fifteen studies were included in the final analysis. Patients with nail psoriasis had higher Psoriasis Area Severity Index and Dermatology Life Quality Index scores than those with psoriasis without nail involvement. The largest percent improvement in QoL score was associated with adalimumab. Studies investigating topicals, intralesionals, and systemic treatments were excluded since only biologic studies utilized validated patient-reported outcome measures. This review affirms that nail psoriasis is physically and emotionally distressing, warranting prompt treatment. Increased efforts are needed to address the impact of treatment on patient QoL using validated outcome measures that assess cosmetic, physical, and social problems.

摘要

至少80%的银屑病患者在其一生中会出现指甲受累情况。了解这种疾病及其相关治疗对生活质量(QoL)的影响至关重要。研究目的是回顾现有文献,描述指甲银屑病患者报告的生活质量结果以及与疾病严重程度和治疗的关系。对2020年8月1日前发表的英文文章进行了文献检索。如果文章呈现了原始数据以及经过验证的评估生活质量的患者报告结局指标,并且专门研究了指甲受累情况,则纳入该综述。最终分析纳入了15项研究。与无指甲受累的银屑病患者相比,指甲银屑病患者的银屑病面积和严重程度指数以及皮肤病生活质量指数得分更高。生活质量得分改善百分比最大的与阿达木单抗相关。由于只有生物制剂研究使用了经过验证的患者报告结局指标,因此排除了研究局部用药、皮损内注射和全身治疗的研究。该综述证实指甲银屑病在身体和情感上令人痛苦,需要及时治疗。需要加大力度,使用评估美容、身体和社会问题的经过验证的结局指标来解决治疗对患者生活质量的影响。